Janus Kinase Inhibitor (JAK) Inhibitors- Competitive Landscape, Technology and Pipeline Analysis, 2016

  • ID: 3784869
  • Drug Pipelines
  • 103 pages
  • DelveInsight
1 of 4

FEATURED COMPANIES

  • AbbVie
  • Advinus
  • Astellas Pharma
  • ATIL
  • BMS
  • CTI BioPharma
  • MORE
“Janus Kinase (JAK) Inhibitors - Competitive Landscape, Technology and Pipeline Analysis, 2016” provides comprehensive insights about pipeline drugs across this Mechanism of action. Key objective of the report is to establish the understanding for all the pipeline drugs that fall under Janus Kinase (JAK) Inhibitors.

This report provides information on the therapeutic development based on JAK Inhibitors mecahanism of action dealing with around 20+ active pipeline drugs. The report also covers the information for 20+ active companies involved in the therapeutic development of the products

Report Highlights:
- The report also includes the information regarding 2 marketed drugs and their current clinical status for various other indications that can touch market in near future.
- This report also has market analysis that covers various deals, agreements, collaborations, acquisitions between various pharma giants and mid-level companies for successful development and future growth of drugs based on this mechanism of action.
- This report provides information on the therapeutic development based on the Janus Kinase (JAK) Inhibitorsdealing with all the marketed and pipeline drugs.
- The report provides drug profile which includes product description, MOA, licensors & collaborators, development partner and chemical information.
- This report covers the comparative analysis of Janus Kinase (JAK) Inhibitors at various stages covering Marketed Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information.
- It also has highlighted the discontinued and dormant products.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by our team of industry experts.
Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.
Please note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated mechanism of action.

***Please note this report requires 48 hours for delivery***
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AbbVie
  • Advinus
  • Astellas Pharma
  • ATIL
  • BMS
  • CTI BioPharma
  • MORE
Table of Contents

- Executive Summary
- Executive Summary Snapshot
- Overview
- Janus kinase Inhibitors (JAK Inhibitors)
- Mechanism of Action
- JAK Inhibitors Market Analysis
- Collaborations and Deals
- Acquisition Deals
- Designations Analysis
- Market Drivers
- Market Barriers
- Pipeline Therapeutics
- Companies Involved
- Therapeutics under Development by Companies
- Marketed and Pre-registration Stage Products
- Marketed Drugs
- Late Stage Products (Phase III)
- Comparative Analysis
- Mid Stage Products (Phase II)
- Comparative Analysis
- Early Stage Products (Phase I)
- Comparative Analysis
- Preclinical Products
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Monotherapy Products
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Dormant Products
- Comparative Analysis
- Companies involved in Therapeutics Development
- SWOT Analysis for JAK inhibitors
- Appendix
- Methodology
- Consulting Services
- About us
- Contact Us
- Disclaimer

List of Tables

Table 1:Collaboration and Deal Values for JAK Inhibitors, 2016
Table 2:Acquisition deals for the development of JAK Inhibitors , 2016
Table 3:Number of Products Under Development for Janus Kinase (JAK) Inhibitors,2016
Table 4: Number of Products under Development by Companies, 2016
Table 5: Marketed and Pre-registration Stage Products,2016
Table 6: Late Stage Products (Phase III),2016
Table 7: Mid Stage Products (Phase II),2016
Table 8: Early Stage Products (Phase I), 2016
Table 9: Preclinical Products, 2016
Table 10: Assessment by Monotherapy Products, 2016
Table 11: Assessment by Route Of Administration, 2016
Table 12:Assessment by Stage and Route Of Administration, 2016
Table 13: Assessment by Molecule Type, 2016
Table 14: Assessment by Stage and Molecule Type, 2016
Table 15: Dormant Products, 2016
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
- AbbVie
- Astellas Pharma
- CTI BioPharma
- Cytopia Research
- Gilead Science
- BMS
- YM BioSciences
- Pfizer
- Eli Lilly
- Advinus
- ATIL
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll